Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
clopidogrel + prasugrel + ticagrelor
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This represents a combination of three distinct P2Y12 receptor inhibitor antiplatelet drugs. Each drug has different pharmacological properties: clopidogrel and prasugrel are thienopyridines that irreversibly inhibit the P2Y12 receptor after hepatic conversion to active metabolites, while ticagrelor is a cyclopentyltriazolopyrimidine that reversibly binds to the P2Y12 receptor without requiring metabolic activation. These drugs are not typically administered simultaneously but may be used in sequence or alternation in specific clinical scenarios for patients with acute coronary syndrome.
- Other names
- clopidogrel/prasugrel/ticagrelor
02
Targets
P2Y12 (Purinergic P2Y12 receptor)
Beyond the preview
Go deeper on clopidogrel + prasugrel + ticagrelor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on clopidogrel + prasugrel + ticagrelor.